Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.

Article  CAS  PubMed  Google Scholar 

Benson AB, Hoffe S, Nurkin S, Overman MJ. NCCN Guidelines Index Table of Contents. 2018;176.

Phelip JM, Tougeron D, Léonard D, Benhaim L, Desolneux G, Dupré A, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51:1357–63.

Article  PubMed  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:329–59.

Article  PubMed  Google Scholar 

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;S0923753422041928.

Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;2335–42.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

Article  CAS  PubMed  Google Scholar 

Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol. 2007;25:1539–44.

Article  CAS  PubMed  Google Scholar 

Simkens LHJ, van Tinteren H, May A, ten Tije AJ, Creemers GJM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal cancer group. Lancet. 2015;385:1843–52.

Article  CAS  PubMed  Google Scholar 

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.

Article  CAS  PubMed  Google Scholar 

Angelucci A, Delle Monache S, Cortellini A, Di Padova M, Ficorella C. “Vessels in the Storm”: searching for prognostic and predictive angiogenic factors in colorectal cancer. Int J Mol Sci. 2018;19:299.

Article  PubMed  PubMed Central  Google Scholar 

Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, et al. Response-Independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008;26:183–9.

Article  CAS  PubMed  Google Scholar 

Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, et al. Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. Ann Oncol. 2016;27:1922–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tranquart F, Dujardin P-A, Bouché O, Marcus C, Borg C, Manzoni P, et al. Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases. Ultraschall Med - Eur J Ultrasound. 2017 [cited 2018 Aug 31]; Available from: http://www.thieme-connect.de/DOI/DOI?https://doi.org/10.1055/s-0043-122497

Chun Y, Vauthey J, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshita H, Hosokawa A, Ueda A, Ando T, Kajiura S, Kato H, et al. Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases. Digestion. 2014;89:43–8.

Article  CAS  PubMed  Google Scholar 

Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, et al. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018;67:1095–102.

Article  CAS  PubMed  Google Scholar 

Masuishi T, Taniguchi H, Eto T, Komori A, Mitani S, Hasegawa H, et al. Morphologic response and tumor shrinkage as early predictive markers in unresectable colorectal liver metastases. Anticancer Res. 2018;38:6501–6.

Article  CAS  PubMed  Google Scholar 

Mazard T, Assenat E, Dupuy M, Mollevi C, René A, Adenis A, et al. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. Dig Liver Dis. 2019;S1590865819305341.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut. 2019;gutjnl-2018–316407.

Bruhn MA, Townsend AR, Khoon Lee C, Shivasami A, Price TJ, Wrin J, et al. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer: proangiogenic proteins and bevacizumab therapy in mCRC. Int J Cancer. 2014;135:731–41.

Article  CAS  PubMed  Google Scholar 

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, et al. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score. Int J Cancer. 2016;139:2325–35.

Article  CAS  PubMed  Google Scholar 

Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, et al. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer. 2017;17:220.

Article  PubMed  PubMed Central  Google Scholar 

Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gómez-España A, la Haba-Rodríguez JRD, et al. Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. Cancers. 2022;14:3054.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambrechts D, Lenz H-J, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219–30.

Article  CAS  PubMed  Google Scholar 

Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015;26:1188–94.

Article  CAS  PubMed  Google Scholar 

Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Kusaba H, Okamura S, et al. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: a post hoc analysis of the WJOG4407G phase III study. Medicine (Baltimore). 2020;99.

Article  CAS  PubMed  Google Scholar 

Dietrich C, Averkiou M, Correas J-M, Lassau N, Leen E, Piscaglia F. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med - Eur J Ultrasound. 2012;33:344–51.

Article  CAS  Google Scholar 

Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, et al. Guidelines and good clinical practice recommendations for Contrast-Enhanced Ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol. 2020;46:2579–604.

Article  PubMed  Google Scholar 

Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, et al. Validation of Dynamic Contrast-Enhanced Ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the french multicenter support for innovative and expensive techniques study. Invest Radiol. 2014;49:794–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mogensen M, Hansen M, Henriksen B, Axelsen T, Vainer B, Osterlind K, et al. Dynamic Contrast-Enhanced Ultrasound of colorectal liver metastases as an imaging modality for early response prediction to chemotherapy. Diagnostics. 2017;7:35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, et al. Dynamic Contrast-Enhanced Ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol. 2018;28:2969–78.

Article  PubMed  Google Scholar 

Wu Z, Yang X, Chen L, Wang Z, Shi Y, Mao H, et al. Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis. Medicine (Baltimore). 2017;96:e6731.

Article  CAS